Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer

A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO stage Ic–IV epithelial ovarian cancer. C-D was given 3-weekly for 6 planned cycles, with a 3-day prophylactic dexamethasone regimen (8 mg b.i.d.). 139...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasey, P A, Atkinson, R, Coleman, R, Crawford, M, Cruickshank, M, Eggleton, P, Fleming, D, Graham, J, Parkin, D, Paul, J, Reed, N S, Kaye, S B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363708/
https://www.ncbi.nlm.nih.gov/pubmed/11161372
http://dx.doi.org/10.1054/bjoc.2000.1572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363708/
https://www.ncbi.nlm.nih.gov/pubmed/11161372
http://dx.doi.org/10.1054/bjoc.2000.1572

Ejemplares similares